Drug Profile
Ciprofloxacin - GSK
Alternative Names: GR 37547Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Anti-infectives; Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors; DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in South Africa (PO, Tablet)
- 28 Aug 2017 GlaxoSmithKline completes a phase I trial in Bacterial infections (In volunteers) in South Africa (PO) (NCT03150082)
- 01 Aug 2017 Phase-I clinical trials in Bacterial infections (In volunteers) in South Africa (PO) (NCT03150082)